| Fiscal Year End | Company Status | Exempt Flag |
| December 31 | Delist | N |
|
|
|
|
|
| Incorporation Locations |
| Inc. Date | Expiry Date | Country | Region | Description |
| 27/Apr/2009 | 15/Jun/2014 | Canada | Alberta | |
|
|
| Exchange Filing Office |
| Location |
| (not available) |
|
|  |
| Business Type(s) |
| Primary/Secondary | Business Type | Details |
| Primary
| *Biotechnology/Biopharmaceutical
| From News Release March 31, 2014 - Aurinia is a clinical stage pharmaceutical company focused on the global nephrology market. Its lead drug, voclosporin, is a novel calcineurin inhibitor. Many members of Aurinia's current leadership team are former senior managers of Aspreva Pharmaceuticals ("Aspreva"), which Galenica acquired for C$ 915 million in 2008. While at Aspreva, this management team executed one of the largest and most important lupus nephritis studies ever conducted, called the Aspreva Lupus Management Study ("ALMS"), which resulted in the emergence of mycophenolate mofetil as a new standard treatment for patients suffering from this devastating and potentially fatal disease. Aurinia holds global rights to all indications for voclosporin and has development and commercialization partners in Canada, Israel, South Africa and Greater China. In addition, Aurinia holds certain rights to exploit the ALMS database.
|
|
|
| Securities |
| Symbol | Security Name | Market | Status |
| *AUP | *Aurinia Pharmaceuticals Inc. | TSX Venture | DELIST |
| *ISA | *Isotechnika Pharma Inc. | TSX Venture | DELIST |
|
|
| Name History | From | To |
| *Aurinia Pharmaceuticals Inc. | 23/Oct/2013 | 15/Jun/2014 |
| *Isotechnika Pharma Inc. | 30/Jul/2013 | 22/Oct/2013 |
|
|
| Company Facts Reconciliation |
| Subject | Date Returned |
| (not available) |
|
|
|
|
|
